BPG is committed to discovery and dissemination of knowledge
Prospective Study
©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 112530
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.112530
Figure 3
Figure 3 Box plot graphs showing laboratory parameters before and after treatment in the hepatocellular carcinoma group compared to the chronic liver disease control group. A: Alpha fetoprotein (AFP) before and after treatment in the hepatocellular carcinoma (HCC) group; B: Telomere length before and after treatment in the HCC group; C: AFP before and after treatment in the HCC and chronic liver disease (CLD) groups; D: Telomere length before and after treatment in the HCC and CLD groups. AFP: Alpha fetoprotein; HCC: Hepatocellular carcinoma; CLD: Chronic liver disease. Asterisks represent the dataset outliers.


Write to the Help Desk